Neoadjuvant versus adjuvant treatment: which one is better for resectable esophageal squamous cell carcinoma?

Table 2 Randomized controlled trials of neoadjuvant chemotherapy versus surgery alone for esophageal squamous cell carcinoma

Study	Histology	SCC (%)	Treatment	n	MS (months)	3-year OS (%)	P value
Schlag [18]	SCC	100	CF	22	7		NS
			Surgery	24	6
Nygaard and colleagues [14]	SCC	100	BC	44	7	3	NS
			Surgery	41	7	9
Maipang and colleagues [19]	SCC	100	BVC	24	17	31	NS
			Surgery	22	17	36
Law and colleagues [20]	SCC	100	CF	74	17	40	NS
			Surgery	73	13	13
Ancona and colleagues [21]	SCC	100	CF	47	25	34^a	NS
			Surgery	47	24	22^a
Kelsen and colleagues [22]	AC/SCC	54	CF	213	15	19^a	NS
			Surgery	227	16	20^a
Allum and colleagues [23]	AC/SCC	31	CF	400	17	43	<0.01
			Surgery	402	13	34

^aFive-year overall survival (OS). AC adenocarcinoma, BC bleomycin + cisplatin, BVC bleomycin + vindesine + cisplatin, CF cisplatin + fluorouracil, MS median survival, NS not significant, SCC squamous cell carcinoma.

ISSN: 1477-7819